The promise and pitfalls of a nicotinic cholinergic approach to pain management

Pain

Volumn 88, Issue 1, 2000, Pages 1-6

  Flores, Christopher M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; EPIBATIDINE; MECAMYLAMINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR;

ANTINOCICEPTION; CHOLINERGIC ACTIVITY; CHOLINERGIC SYSTEM; HUMAN; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; REVIEW; SENSORY NERVE CELL;

ANALGESICS; ANIMAL; HUMAN; NICOTINIC AGONISTS; PALLIATIVE CARE;

EID: 0034307124     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(00)00389-4     Document Type: Review

References (52)

1. Aceto M.D., Awaya H., Martion B.R., May E.L. Antinociceptive action of nicotine and its methiodide derivatives in mice and rats. Br J Pharm. 79:1983;869-876.
2. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders, 4th edn. (DSM IV). 1994.
3. Badio B., Daly J.W. Epibatidine, a potent analgetic and nicotinic agonist. Mol Pharmacol. 45:1994;563-569.
4. Bannon A.W., Gunther K.L., Decker M.W. Is epibatidine really analgesic? Dissociation of the activity, temperature, and analgesic effects of (±)-epibatidine. Pharmacol Biochem Behav. 51:1995;693-698.
5. Bannon A.W., Decker M.W., Curzon P., Buckley M.J., Kim D.J.B., Radek R.J., Lynch J.K., Wasicak J.T., Lin N.-H., Arnold W.H., Holladay M.W., Williams M., Arneric S.P. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. in vivo characterization. J Pharmacol Exp Ther. 285:1998;787-794.
6. Bannon A.W., Decker M.W., Holladay M.W., Curzon P., Donnelly Roberts D., Puttfarcken P.S., Bitner S., Diaz A., Dickenson A.H., Porsolt R.D., Williams M., Arneric S.P. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science. 279:1998;77-80.
7. 3H]-nicotine binding sites in human brain. J Neurochem. 50:1988;1243-1247.
8. Bitner R.S., Nikkel A.L., Curzon P., Arneric S.P., Bannon A.W., Decker M.W. Role of the nucleus raphe magnus in antinociception produced by ABT-594: immediate early gene responses possibly linked to neuronal nicotinic acetylcholine receptors on serotonergic neurons. J Neurosci. 18:1998;5426-5432.
9. Bitner R.S., Nikkel A.L., Curzon P., Donnelly-Roberts D.L., Puttfarcken P.S., Namovic M., Jacobs I.C., Meyer M.D., Decker M.W. Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat. Brain Res. 871:2000;66-74.
10. Boyce S., Webb J.K., Shepheard S.L., Russell M.G.N., Hill R.G., Rupniak N.M.J. Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats. Pain. 85:2000;443-450.
11. Caggiula A.R., Epstein L.H., Perkins K.A., Saylor S. Different methods of assessing nicotine-induced antinociception may engage different neural mechanisms. Psychopharmacology. 122:1995;301-306.
12. Chiari A., Tobin J.R., Pan H-L., Hood D.D., Eisenach J.C. Sex differences in cholinergic analgesia I, a supplemental nicotinic mechanism in normal females. Anesthesiology. 91:1999;1447-1454.
13. Craft R.M., Milholland R.B. Sex differences in cocaine- and nicotine-induced antinociception in the rat. Brain Res. 809:1998;137-140.
14. Curzon P., Nikkel A.L., Bannon A.W., Arneric S.P., Decker M.W. Differences between the antinociceptive effects of the cholinergic channel activators A-85380 and (±)-epibatidine in rats. J Pharmacol Exp Ther. 287:1998;847-853.
15. Damaj M.I., Martin B.R. Tolerance to the antinociceptive effect of epibatidine after acute and chronic administration in mice. Eur J Pharmacol. 300:1996;51-57.
16. Davis L., Pollock L.J., Stone T.T. Visceral pain. Surg Gynecol Obstet. 55:1932;418-426.
17. Davison G., Duffy M. Smoking habits of long-term survivors of surgery for lung cancer. Thorax. 37:1982;331-333.
18. Donnelly-Roberts D.L., Puttfarcken P.S., Kuntzweiler T.A., Briggs C.A., Anderson D.J., Campbell J.E., Piattoni-Kaplan M., McKenna D.G., Wasicak J.T., Holladay M.W., Williams M., Arneric S.P. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. in vitro characterization. J Pharmacol Exp Ther. 285:1998;777-786.
19. Dussor G.O., Leong A.S., Gracia N.B., Hargreaves K.M., Arneric S.P., Flores C.M. Differential effects of neuronal nicotinic receptor agonists on capsaicin-evoked CGRP release from peripheral terminals of primary sensory neurons. Soc Neurosci Abstr. 24:1998;1625.
20. Francel P.C., Harris K., Smith M., Fishman M.C., Dawson G., Miller R.J. Neurochemical characteristics of a novel dorsal root ganglion X neuroblastoma hybrid cell line. F-11. J Neurochem. 48:1987;1624-1631.
21. Flores C.M., Hargreaves K.M. Neuronal nicotinic receptors: new targets in the treatment of pain. Arneric S.P., Brioni J.D., Neuronal nicotinic receptors: pharmacology and therapeutic opportunities. 1998;359-378 Wiley-Liss Inc, New York.
22. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., Kellar K.J. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol. 41:1992;31-37.
23. Flores C.M., DeCamp R.M., Kilo S., Rogers S.W., Hargreaves K.M. Neuronal nicotinic receptor expression in sensory neurons of the rat trigeminal ganglion: demonstration of α3β4, a novel subtype in the mammalian nervous system. J Neurosci. 16:1996;7892-7901.
24. Flores C.M., Wilson S.G., Mogil J.S. Pharmacogenetic variability in neuronal nicotinic receptor-mediated antinociception. Pharmacogenetics. 9:1999;619-625.
25. Hulihan-Giblin B.A., Lumpkin M.D., Kellar K.J. Acute effects of nicotine on prolactin release in the rat: agonist and antagonist effects of a single injection of nicotine. J Pharmacol Exp Ther. 252:1990;15-20.
26. Hulihan-Giblin B.A., Lumpkin M.D., Kellar K.J. Effects of chronic administration of nicotine on prolactin release in the rat: inactivation of prolactin response by repeated injections of nicotine. J Pharmacol Exp Ther. 252:1990;21-25.
27. Iwamoto E.T., Marion L. Adrenergic, serotonergic and cholinergic components of nicotinic antinociception in rats. J Pharmacol Exp Ther. 265:1993;777-789.
28. Jamner L.D., Girdler S.S., Shapiro D., Jarvik M.E. Pain inhibition, nicotine and gender. Exp Clin Psychopharmacol. 6:1998;96-106.
29. Jancsó N., Jancsó-Gábor, Takáts I. Pain and inflammation induced by nicotine, acetylcholine and structurally related compounds and their prevention by desensitizing agents. Acta Physiol. 19:1961;113-132.
30. Keele C.A., Armstrong D. Substances producing pain and itch. 1964;107-123 Edward Arnold Ltd, London.
31. Keiger C.J.H., Walker J.C. Individual variation in the expression profiles of nicotinic receptors in the olfactory bulb and trigeminal ganglion and identification of α2α6, α9, and β3 transcripts. Biochem Pharmacol. 59:2000;233-240.
32. Kesingland A.C., Gentry C.T., Panesar M.S., Bowes M.A., Vernier J-M., Cube R., Walker K., Urban L. Analgesic profile of the nicotinic acetylcholine receptor agonists, (+)-epibatidine and ABT-594 in models of persistent inflammatory and neuropathic pain. Pain. 86:2000;113-118.
33. Koylu E., Demirgören S., London E.D., Pögün S. Sex difference in up-regulation of nicotinic acetylcholine receptors. Life Sci. 61:1997;185-190.
34. Lavand'homme P.M., Eisenach J.C. Sex differences in cholinergic analgesia II, differing mechanisms in two models of anllodynia. Anesthesiology. 91:1999;1455-1461.
35. Liu L., Pugh W., Ma H., Simon S.A. Identification of acetylcholine receptors in adult rat trigeminal ganglion neurons. Brain Res. 617:1993;37-42.
36. Liu L., Chang G-Q., Jiao Y.Q., Simon S.A. Neuronal nicotinic acetylcholine receptors in rat trigeminal ganglia. Brain Res. 809:1998;238-245.
37. Lloyd G.K., Williams M. Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther. 292:2000;461-467.
38. Marubio L.M., del Mar Arroyo-Jimenez M., Cordero-Erausquin M., Léna C., Le Novère N., de Kerchove d'Exaerde A., Huchet M., Damaj M.I., Changeux J.-P. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature. 398:1999;805-810.
39. Mogil J. The genetic mediation of individual differences in sensitivity to pain and its inhibition. Proc Natl Acad Sci USA. 96:1999;7744-7751.
40. Mogil J.S., Kest B. Sex differences in opioid analgesia. Pain Forum. 8:1999;48-50.
41. Perry D.C., Davila-Garcia M.I., Stockmeier C.A., Kellar K.J. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exp Ther. 289:1999;1545-1552.
42. Polz-Tejera G., Hunt S.P., Schmidt J. Nicotinic receptors in sensory ganglia. Brain Res. 195:1980;223-230.
43. Puttfarcken P.S., Manelli A.M., Arneric S.P., Donnelly-Roberts D.L. Evidence for nicotinic receptors potentially modulating nociceptive transmission at the level of the primary sensory neuron: studies with F11 cells. J Neurochem. 69:1997;930-938.
44. Qian C., Li T., Shen T.Y., Libertine-Garahan L., Eckman J., Biftu T., Ip S. Epibatidine is a nicotinic analgesic. Eur J Pharmacol. 250:1993;R13-R14.
45. Roberts R.G.D., Stevenson J.E., Westerman R.A., Pennefather J. Nicotinic acetylcholine receptors on capsaicin-sensitive nerves. NeuroReport. 6:1995;1578-1582.
46. Spande T.F., Garraffo H.M., Edwards M.W., Yeh H.J.C., Pannel L., Daly J.W. Epibatidine: a novel (chloropyridyl)azabicycloheptane with potent analgesic activity from an ecuadoran poison frog. J Am Chem Soc. 14:1992;3475-3478.
47. Steen K., Reeh P. Actions of cholinergic agonists and antagonists on sensory nerve endings in rat skin in vitro. J Neurophysiol. 70:1993;397-405.
48. Sucher N.J., Cheng T.P.O., Lipton S.A. Neural nicotinic acetylcholine responses in sensory neurons from postnatal rat. Brain Res. 533:1990;248-254.
49. Suh H.W., Song D.K., Choi S.R., Chung K.M., Kim Y.H. Nicotine enhances morphine- and beta-endorphin-induced antinociception at the supraspinal level in the mouse. Neuropeptides. 30:1996;479-484.
50. 2,5-enkephalin and U50,488H administered intrathecally in the mouse. Neuropeptides. 30:1996;373-378.
51. Sullivan J.P., Decker M.W., Brioni J.D., Donnelly-Roberts D., Anderson D.J., Bannon A.W., Kang C-H., Adams P., Piattoni-Kaplan M., Buckley M.J., Gopalakrishnan M., Williams M., Arneric S.P. (±)Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J Pharmacol Exp Ther. 271:1994;624-631.
52. Taylor P. Agents acting at the neuromuscular junction and autonomic ganglia. Hardma J.G., Limbird L.E., Goodman & Gilman's: the pharmacological basis of therapeutics. 9th edn :1995;177-197 McGraw-Hill, New York.